Insmed Inc (INSM) Com Stock USD 0.01
Sell:$102.53Buy:$102.58
$1.59
(1.53%)
0.05%- This stock can be held in a
Stocks and Shares ISA$1.59
(1.53%)$1.59
(1.53%)Company Information
About this company
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Key people
Key facts
- EPICINSM
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS4576693075
- Market cap$19.84bn
- Employees1,271
- Shares in issue189.71m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.